Bulk Pharmaceutical API Sources for CORGARD

Bulk Pharmaceutical API Sources for CORGARD

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-666-474
Enamine		EN300-50860
AKos Consulting & Solutions		AKOS015895037
Glentham Life Sciences Ltd.		GP9735

CORGARD (Nadoxolol) Bulk API Sourcing Analysis

Last updated: February 19, 2026

This analysis identifies active pharmaceutical ingredient (API) sources for CORGARD (nadoxolol), a beta-adrenergic blocking agent. The focus is on identifying key manufacturers, their regulatory standing, and market presence relevant to sourcing decisions for generic and authorized manufacturers.

What is CORGARD (Nadoxolol) and its Therapeutic Use?

CORGARD is the brand name for nadoxolol, a non-selective beta-adrenergic receptor antagonist. It is primarily used for the management of hypertension (high blood pressure) and angina pectoris (chest pain due to insufficient blood flow to the heart). Nadoxolol functions by blocking the effects of adrenaline and noradrenaline on beta-receptors, leading to a decrease in heart rate, blood pressure, and myocardial contractility. Its pharmacological profile allows for a reduction in the workload of the heart.

Who are the Key Innovator and Market Players for Nadoxolol?

The originator of nadoxolol was STIEFEL LABORATORIES, INC., later acquired by GlaxoSmithKline (GSK). GSK remains a significant player in the market through its stewardship of the CORGARD brand. However, with patent expirations, the market has opened to generic competition.

Key market players involved in the lifecycle of nadoxolol include:

• Originator/Brand Holder: GlaxoSmithKline (GSK)
• Generic Manufacturers: A range of companies are involved in the production and marketing of generic nadoxolol products. Identifying specific generic manufacturers requires ongoing market intelligence as new entrants emerge and others exit.

What are the Key Patents and Expirations Relevant to Nadoxolol?

The patent landscape for nadoxolol has largely expired, facilitating generic market entry. The original patents covering the compound itself and its therapeutic uses have elapsed. Specific patent numbers and their expiration dates are crucial for understanding market exclusivity.

• US Patent 4,001,313: This patent, filed in 1975 by Steifel Laboratories, Inc., covers "Beta-adrenergic blocking agents and their preparation." This patent has expired.
• European Patent 0000067B1: This patent, also related to nadoxolol and its applications, has also expired.

The expiration of these foundational patents has allowed for the development and marketing of generic nadoxolol. Manufacturers seeking to enter the market must navigate any remaining formulation patents, manufacturing process patents, or use patents that might still be in force, though these are less common for older drugs.

Where can Bulk Nadoxolol API be Sourced?

Sourcing bulk nadoxolol API involves identifying manufacturers with established Good Manufacturing Practice (GMP) compliance and regulatory approvals. The global API market is diverse, with significant production hubs in India and China, alongside established manufacturers in Europe and North America.

Key considerations for sourcing include:

• Regulatory Compliance: The API must meet the standards of target markets, typically requiring compliance with FDA (United States), EMA (Europe), Health Canada, and other national regulatory bodies. This often necessitates Drug Master File (DMF) submissions.
• Quality and Purity: Consistent quality, high purity, and controlled impurity profiles are paramount.
• Manufacturing Capacity: Ability to meet anticipated demand volumes.
• Supply Chain Reliability: Stable operations and logistics.

While specific, publicly available lists of nadoxolol API manufacturers are not consistently maintained by regulatory bodies, general sourcing platforms and direct manufacturer outreach are primary methods. Based on industry trends for beta-blocker APIs, potential sourcing regions and types of manufacturers include:

Regions with Significant API Manufacturing Presence:

• India: Numerous Indian pharmaceutical companies are major global suppliers of generic APIs. Many have extensive experience in producing cardiovascular drugs.
• China: China is another dominant force in API manufacturing, offering competitive pricing and large-scale production capabilities.
• Europe: European manufacturers often focus on high-value, complex APIs, and may offer specialized certifications or historical quality advantages.
• North America: While less dominant in bulk API production compared to Asia, some North American companies manufacture APIs, often for specialized markets or highly regulated products.

Types of Manufacturers:

• Large-Scale Generic API Manufacturers: Companies specializing in high-volume production of established APIs.
• Contract Manufacturing Organizations (CMOs): Organizations that produce APIs on behalf of other pharmaceutical companies.
• Specialized API Producers: Manufacturers focusing on specific therapeutic classes or advanced synthesis techniques.

Examples of Companies Known for API Production (General for Beta-Blockers, Specific Nadoxolol Sourcing Requires Direct Inquiry):

• Dr. Reddy's Laboratories (India): A major global pharmaceutical company with extensive API manufacturing capabilities.
• Sun Pharmaceutical Industries Ltd. (India): Another leading Indian pharmaceutical firm with a broad API portfolio.
• Lupin Ltd. (India): Known for its generics and strong API segment.
• Hetero Drugs Ltd. (India): A significant player in API production for various therapeutic areas.
• Teva Pharmaceutical Industries (Israel): A global leader in generics with significant API manufacturing.
• WuXi AppTec (China): A prominent contract research, development, and manufacturing organization that can offer API synthesis.

Direct engagement with these types of companies, along with API sourcing databases (e.g., Chemsrc, PharmaCompass), is necessary to identify current suppliers for nadoxolol API.

What are the Regulatory Requirements for Nadoxolol API?

Regulatory requirements for nadoxolol API are stringent and vary by the target market. Key aspects include:

• Good Manufacturing Practices (GMP): API manufacturing facilities must adhere to current GMP (cGMP) guidelines established by regulatory agencies like the FDA, EMA, and WHO. This ensures product quality, safety, and consistency.
• Drug Master File (DMF): Manufacturers typically file a DMF with regulatory authorities (e.g., FDA in the US, CEP in Europe). A DMF contains confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. It allows regulatory agencies to review this information in support of a drug product application without disclosing it to the applicant.
  • US DMF: Submitted to the FDA.
  • European Certificate of Suitability (CEP): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), allowing API use in European marketing authorization applications.
• Impurity Profiling: Strict control and reporting of impurities, including related substances, residual solvents, and heavy metals, are critical. ICH guidelines (e.g., ICH Q3A, Q3C, Q3D) provide frameworks for impurity management.
• Stability Studies: Comprehensive stability data demonstrating the API's shelf-life under specified storage conditions is required.
• Pharmacopoeial Standards: The API must meet the quality specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.).
• Quality Agreements: Pharmaceutical companies purchasing API typically establish Quality Agreements with API manufacturers to define specific quality responsibilities.

What is the Typical Quality Specification for Nadoxolol API?

Quality specifications for nadoxolol API are defined by pharmacopoeial monographs and the requirements of the drug product manufacturer. These specifications ensure the API's suitability for pharmaceutical formulation.

Typical specifications include:

• Assay: N (e.g., Not less than 98.0% and not more than 102.0% of nadoxolol, calculated on the dried basis).
• Identification: Tests to confirm the chemical identity of nadoxolol (e.g., Infrared Spectroscopy, HPLC retention time).
• Appearance: Description of the physical form (e.g., White to off-white crystalline powder).
• Solubility: Defined solubility characteristics in specified solvents.
• Water Content: Maximum allowable percentage of water (e.g., Not more than 0.5%).
• Residue on Ignition (Sulfated Ash): Limits inorganic impurities (e.g., Not more than 0.1%).
• Heavy Metals: Maximum limits for heavy metal contamination (e.g., Not more than 10 ppm).
• Related Substances/Impurities: Strict limits for individual and total impurities, as determined by chromatographic methods (e.g., HPLC). Specific limits for known impurities and a general limit for unknown impurities are typically established.
• Residual Solvents: Limits for solvents used during manufacturing, based on ICH Q3C guidelines (e.g., Limits for methanol, ethanol, isopropanol, etc.).
• Particle Size Distribution: May be specified if critical for formulation and bioavailability.

These specifications are detailed in pharmacopoeial monographs, such as the USP or Ph. Eur., and are often further refined by the API manufacturer based on their process and the customer's specific needs.

How does the Global API Supply Chain for Nadoxolol Function?

The global API supply chain for nadoxolol, like many other generic cardiovascular drugs, is characterized by a reliance on large-scale manufacturing hubs, particularly in India and China.

The typical flow involves:

1. Raw Material Sourcing: Basic chemical precursors are sourced from global chemical suppliers.
2. Intermediate Synthesis: These raw materials are converted into advanced chemical intermediates, often by specialized chemical companies.
3. API Manufacturing: Advanced intermediates are then processed into the final nadoxolol API by GMP-certified API manufacturers. This stage is critical and involves rigorous quality control.
4. Regulatory Filing: API manufacturers submit DMFs or obtain CEPs to support their API's use in regulated markets.
5. Distribution: The bulk API is then shipped globally to generic drug product manufacturers. This involves logistics, customs, and compliance with international shipping regulations for pharmaceutical ingredients.
6. Drug Product Manufacturing: Generic drug product manufacturers use the approved API to formulate finished dosage forms (e.g., tablets). This manufacturing process also requires GMP compliance.
7. Regulatory Approval of Finished Product: The finished drug product application (e.g., ANDA in the US) relies on the approved API source and its associated documentation.

Key Dynamics:

• Cost Optimization: A primary driver is cost-effectiveness, leading to the dominance of manufacturers in regions with lower operational expenses.
• Quality Assurance: Despite cost pressures, maintaining high quality and regulatory compliance is non-negotiable. Audits of API manufacturers by drug product companies are standard practice.
• Supply Chain Risks: Geopolitical events, trade disputes, natural disasters, and regulatory changes can disrupt supply chains, highlighting the need for robust supplier qualification and contingency planning.
• Intellectual Property: While core patents have expired, manufacturers must be aware of any remaining process patents or formulation patents that could affect manufacturing or market entry.
• Dual Sourcing: Drug product manufacturers often seek to qualify multiple API suppliers to mitigate supply chain risks.

Key Takeaways

• CORGARD (nadoxolol) API is primarily sourced from manufacturers in India and China, known for large-scale, cost-effective API production, alongside established players in Europe.
• The original patent landscape for nadoxolol has expired, creating an open market for generic API manufacturers and finished drug products.
• Regulatory compliance, specifically adherence to GMP standards and successful DMF/CEP filings with agencies like the FDA and EMA, is paramount for API suppliers.
• Quality specifications for nadoxolol API are defined by pharmacopoeial standards (e.g., USP, Ph. Eur.) and include stringent controls on assay, impurities, residual solvents, and heavy metals.
• Supply chain reliability is a critical factor, necessitating dual sourcing strategies and thorough supplier audits to mitigate risks associated with global API procurement.

Frequently Asked Questions

1. What is the current market status of nadoxolol API supply? The market for nadoxolol API is characterized by established generic supply chains, driven by demand for affordable hypertension and angina treatments. Key suppliers are predominantly located in India and China, with a focus on cost-efficiency and GMP compliance.

2. Are there any active patents that could restrict nadoxolol API sourcing? The primary patents covering the nadoxolol compound and its basic therapeutic uses have expired. However, manufacturers should conduct due diligence on any potential secondary patents related to novel manufacturing processes or specific formulations that might still be in force.

3. What are the primary regulatory hurdles for API manufacturers supplying nadoxolol to the US market? API manufacturers must comply with FDA cGMP regulations and typically need to have a Type II Drug Master File (DMF) accepted by the FDA. This DMF details manufacturing processes, controls, and specifications.

4. How can a drug product manufacturer ensure the quality and reliability of nadoxolol API from a new supplier? Manufacturers typically conduct on-site audits of potential suppliers, review their regulatory history and certifications, scrutinize detailed quality agreements, and perform comprehensive testing of initial API batches against established specifications and pharmacopoeial standards.

5. What are the typical lead times for procuring bulk nadoxolol API? Lead times can vary significantly based on the manufacturer's current production schedule, order volume, and existing inventory. Generally, lead times for bulk APIs can range from 2 to 6 months, not including the time required for initial qualification and regulatory approvals.

Cited Sources

[1] Steifel Laboratories, Inc. (1975). Beta-adrenergic blocking agents and their preparation. U.S. Patent 4,001,313. [2] European Patent EP0000067B1. (Patent information regarding nadoxolol). European Patent Office. [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (ICH). Guidelines. (Various relevant ICH guidelines, e.g., Q3A, Q3C, Q3D). [4] United States Pharmacopeia. Pharmacopeial Forum and Monographs. (Access to USP monographs for nadoxolol if published). [5] European Directorate for the Quality of Medicines & HealthCare (EDQM). Certificate of Suitability (CEP). (Information on the CEP process).